- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- educational intervention
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 9,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Interventions
- VV-14303
- Genetic
- Lead sponsor
- Kriya Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Lady Lake, Florida
- Conditions
- Limbal Stem Cell Deficiency
- Interventions
- LSC2
- Biological
- Lead sponsor
- RHEACELL GmbH & Co. KG
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- TAK-058, TAK-058 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austsitn, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- MEDI1873
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 7 more
- Conditions
- Advanced Solid Tumors
- Interventions
- GS-2121, Zimberelimab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Boston, Massachusetts • San Antonio, Texas + 1 more
- Conditions
- Healthy
- Interventions
- RDEA3170 10 mg, Febuxostat 40 mg, placebo
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Myelodysplastic Syndrome
- Interventions
- decitabine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Rochester, Minnesota + 3 more
- Conditions
- Hepatic Impairment
- Interventions
- Quizartinib
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Miami, Florida • St. Petersburg, Florida
- Conditions
- Advanced Nonhematological Malignancies
- Interventions
- TAK-960
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Plaque Psoriasis
- Interventions
- ARQ-151- cream 0.3%
- Drug
- Lead sponsor
- Arcutis Biotherapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 12
- States / cities
- Rogers, Arkansas • Fountain Valley, California • Coral Gables, Florida + 9 more
- Conditions
- Locally Advanced or Metastatic Non Small Cell Lung Cancer
- Interventions
- Rociletinib
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 39
- States / cities
- Duarte, California • Fountain Valley, California • Los Angeles, California + 32 more
- Conditions
- Solid Malignancies, Hematologic Malignancies
- Interventions
- IM-1021
- Drug
- Lead sponsor
- Immunome, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 19
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 16 more
- Conditions
- Healthy
- Interventions
- Talampanel, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
- Interventions
- SBT6050, trastuzumab deruxtecan, tucatinib, trastuzumab, capecitabine
- Drug
- Lead sponsor
- Silverback Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
- Interventions
- SGN-ALPV
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Fresno, California • New Haven, Connecticut • Wellington, Florida + 4 more
- Conditions
- Non Small Cell Lung Cancer, CNS Progression
- Interventions
- Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- High Point, North Carolina • San Antonio, Texas
- Conditions
- Glioblastoma Multiforme
- Interventions
- Perillyl alcohol
- Drug
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Santa Monica, California + 7 more
- Conditions
- Alzheimer's Disease
- Interventions
- Velusetrag, Placebo
- Drug
- Lead sponsor
- Alfasigma S.p.A.
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Miramar, Florida
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Melanoma, CRC, Urothelial Carcinoma, Cholangiocarcinoma
- Interventions
- NC318
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 3 more
- Conditions
- Opioid Overdose
- Interventions
- Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection
- Drug
- Lead sponsor
- Knoa Pharma LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Mantle Cell Lymphoma (MCL)
- Interventions
- Copanlisib, Ibrutinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Multiple Myeloma, NonHodgkin Lymphoma
- Interventions
- TAS4464
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 7
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Farmington Hills, Michigan + 4 more